Halozyme Therapeutics, Inc. (NASDAQ:HALO)

CAPS Rating: 3 out of 5

A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.

Recs

0
Player Avatar pchop123 (76.58) Submitted: 9/18/2012 12:49:11 PM : Outperform Start Price: $6.31 HALO Score: +25.30

insider buying

Featured Broker Partners


Advertisement